Reviva to Host Virtual Event on Vocal Biomarker Data from Brilaroxazine Phase 3 Schizophrenia Trial on Sep 4, 2024

Reviva Pharmaceuticals Holdings, Inc., a pharmaceutical company focused on addressing unmet medical needs in central nervous system, inflammatory, and cardiometabolic diseases, is set to host a virtual event featuring key opinion leaders (KOL) on September 4, 2024, at 2:00 PM ET. This event will spotlight Dr. Brian Kirkpatrick and Dr. Mark Opler, who are experts in the field of schizophrenia research and treatment.

Dr. Brian Kirkpatrick is a Professor at the Psychiatric Research Institute of the University of Arkansas for Medical Sciences. He is recognized nationally and internationally for his contributions to schizophrenia research. Dr. Kirkpatrick has a robust academic background, having earned his MD from the University of Texas Medical School at Houston, followed by a psychiatry residency and a fellowship in neuropharmacology at the University of North Carolina at Chapel Hill. Throughout his career, he has held significant positions in various institutions including the University of Maryland School of Medicine, Medical College of Georgia, Texas A&M School of Medicine, and the University of Nevada, Reno School of Medicine. His research has been funded by prominent organizations such as the National Institute of Mental Health (NIMH) and the Brain and Behavior Research Foundation.

Dr. Mark Opler, Chief Research Officer at WCG Inc. and Executive Director of the PANSS Institute, has an extensive background in the etiology and treatment of persistent mental disorders. His academic journey includes a PhD and MPH from Columbia University and a BSc from SUNY at Stony Brook. Dr. Opler has also contributed to the development of clinical assessment tools like SNAPSI, CGI-DS, and NY-AACENT, and has received funding from NIMH and the Brain & Behavior Foundation, among others. He has authored over 50 peer-reviewed publications and numerous book chapters on mental health.

The upcoming event will delve into the unmet medical needs and current treatment landscape for schizophrenia, particularly focusing on the use of speech latency as an objective vocal biomarker in clinical trials. The discussion will include a review of data from the brilaroxazine Phase 3 RECOVER-1 trial, which aims to treat symptoms of schizophrenia. The primary and secondary efficacy endpoints, such as negative symptoms, social functioning, and social cognition, will be examined. The event will conclude with a live question and answer session, allowing attendees to engage directly with the experts.

Brilaroxazine, a chemical entity with high affinity for serotonin and dopamine receptors, has shown promise in treating conditions including schizophrenia, psoriasis, and certain lung diseases. The Phase 3 RECOVER-1 trial has reported positive topline data, indicating that the drug meets all primary and secondary endpoints with significant reductions in symptoms and a side effect profile similar to placebo.

Reviva Pharmaceuticals, the company behind brilaroxazine, is dedicated to developing next-generation therapeutics for diseases with unmet medical needs. Their pipeline includes brilaroxazine and another compound, RP1208, both of which have received patents in the United States and Europe. Brilaroxazine has also shown potential in nonclinical studies for treating inflammatory diseases such as psoriasis and pulmonary arterial hypertension (PAH).

Overall, Reviva’s focus on developing innovative treatments for complex conditions positions them as a significant player in the biopharmaceutical industry. The virtual KOL event promises to provide valuable insights into the latest advancements in schizophrenia treatment, particularly through the use of cutting-edge biomarkers like speech latency.